SUN-257 Adherence Rates to Growth Hormone Therapy: ECOS Study Analysis of Australian Data Compared with Global Adherence Rates

Background: The ECOS observational study was a long term, multicentre, observational study that looked at assessing the level of adherence to paediatric patients’ prescribed recombinant GH (r-hGH) Saizen (somatropin) via the Easypod® electromechanical auto-injector device, and to then further analyse possible clinical and socioeconomic factors that influence adherence. Aim: To evaluate and compare Australian adherence rates of r-hGH compared with existing global data. Method: Adherence data was determined directly from data downloaded from each Easypod device, while standard baseline and outcomes measures were obtained directly from patient medical notes including socioeconomic, demographic, auxological and diagnostic data. Patients were included on the basis of eligibility for subsidised hGH - diagnoses included growth hormone deficiency (GHD), (sub-analysed as prior GH exposure and GH-naive), small for gestation age, those with chronic renal insufficiency and girls with Turner syndrome. The following data was collected on all patients with a complete data set (CAS): (CAS: Easypod start date documented, no gap in injection data of more than a week, and height documented at baseline and 1 year after the start of easypod). Results: Globally 2417 patients were analysed and, within this, 1203 met the complete data set analysis set (CAS) and were further analysed. The Australian cohort consisted of 28 patients of whom 19 had a complete CAS. This included patients with both GHD (n = 13) and Turner syndrome (n = 6). The median adherence rate was 98.4% at 1 year and 92.6% at 4 years. There was a positive correlation between adherence and change in height (cms), r = 0.739 p = 0.0061 and adherence and height velocity (cms), r = 0.664 p = 0.023, for patients with GHD The greatest response was seen in the GH-naïve dataset. 13 patients had a medium change at 1-year SDS >0.5, indicating an equal to greater positive response. Conclusion: The Australian data from the ECOS study provides additional information regarding adherence to Growth Hormone therapy and growth outcomes. Electronic monitoring potentially provides clinicians an early opportunity to address adherence in a timely manner to promote maximum outcomes.